Aldose reductase drives hyperacetylation of EGR-1 in hyperglycemia and consequent upregulation of proinflammatory and prothrombotic signals

Diabetes

Volumn 63, Issue 2, 2014, Pages 761-774

  Vedantham, Srinivasan ^a   Thiagarajan, Devi ^a   Ananthakrishnan, Radha ^a   Wang, Lingjie ^a   Rosario, Rosa ^a   Zou, Yu Shan ^a   Goldberg, Ira ^b   Yan, Shi Fang ^a   Schmidt, Ann Marie ^a   Ramasamy, Ravichandran ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; EARLY GROWTH RESPONSE FACTOR 1; GLUCOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESVERATROL; SIRTUIN 1; STREPTOZOCIN; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; CONTROLLED STUDY; DEACETYLATION; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HOMEOSTASIS; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSIENT TRANSFECTION; UPREGULATION; WESTERN BLOTTING;

ALDEHYDE REDUCTASE; ANIMALS; APOLIPOPROTEINS E; CELLS, CULTURED; CYTOKINES; EARLY GROWTH RESPONSE PROTEIN 1; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPERGLYCEMIA; MICE; MICE, TRANSGENIC; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SIRTUIN 1; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84893135642     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0032     Document Type: Article

References (45)

1. Shukla V, Vaissière T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008;637:1-15
2. Campos EI, Reinberg D. Histones: annotating chromatin. Annu Rev Genet 2009;43:559-599
3. Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325: 834-840
4. Wang Q, Zhang Y, Yang C, et al. Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science 2010;327: 1004-1007
5. Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010;327:1000-1004
6. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403:795-800
7. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000;14:1021-1026
8. Cheng HL, Mostoslavsky R, Saito S, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003;100:10794-10799
9. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-148
10. Daitoku H, Hatta M, Matsuzaki H, et al. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc Natl Acad Sci USA 2004;101:10042-10047
11. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429:771-776
12. Rothgiesser KM, Erener S, Waibel S, Lüscher B, Hottiger MO. SIRT2 regulates NF-kB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 2010;123:4251-4258
13. Breitenstein A, Stein S, Holy EW, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res 2011;89:464-472
14. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434:113-118
15. Vikramadithyan RK, Hu Y, Noh HL, et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest 2005;115:2434-2443
16. Vedantham S, Noh H, Ananthakrishnan R, et al. Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/-mice. Arterioscler Thromb Vasc Biol 2011;31:1805-1813
17. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-813
18. Yamaoka T, Nishimura C, Yamashita K, et al. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA. Diabetologia 1995;38:255-261
19. Kobayashi M, Inoue K, Warabi E, Minami T, Kodama T. A simple method of isolating mouse aortic endothelial cells. J Atheroscler Thromb 2005;12: 138-142
20. Yu J, de Belle I, Liang H, Adamson ED. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr-1 in prostate cells, leading to divergent responses. Mol Cell 2004;15:83-94
21. Gupta MP, Samant SA, Smith SH, Shroff SG. HDAC4 and PCAF bind to cardiac sarcomeres and play a role in regulating myofilament contractile activity. J Biol Chem 2008;283:10135-10146
22. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790
23. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
24. Cheng HM, González RG. The effect of high glucose and oxidative stress on lens metabolism, aldose reductase, and senile cataractogenesis. Metabolism 1986;35(Suppl. 1):10-14
25. Ishii H, Tada H, Isogai S. An aldose reductase inhibitor prevents glucoseinduced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia 1998;41:362-364
26. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866
27. Wendt T, Bucciarelli L, Qu W, et al. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 2002;4:228-237
28. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol Sci 2010;31:212-220
29. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet-and age-induced diabetes in mice. Cell Metab 2011;14:528-536
30. Hasan RN, Phukan S, Harada S. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:988-993
31. Gousseva N, Kugathasan K, Chesterman CN, Khachigian LM. Early growth response factor-1 mediates insulin-inducible vascular endothelial cell proliferation and regrowth after injury. J Cell Biochem 2001;81:523-534
32. McCaffrey TA, Fu C, Du B, et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest 2000;105:653-662
33. Ahmed MM, Venkatasubbarao K, Fruitwala SM, et al. EGR-1 induction is required for maximal radiosensitivity in A375-C6 melanoma cells. J Biol Chem 1996;271:29231-29237
34. Wang B, Chen J, Santiago FS, et al. Phosphorylation and acetylation of histone H3 and autoregulation by early growth response 1 mediate interleukin 1beta induction of early growth response 1 transcription. Arterioscler Thromb Vasc Biol 2010;30:536-545
35. Ahmed MM, Sells SF, Venkatasubbarao K, et al. Ionizing radiation-inducible apoptosis in the absence of p53 linked to transcription factor EGR-1. J Biol Chem 1997;272:33056-33061
36. Calogero A, Arcella A, De Gregorio G, et al. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 2001;7:2788-2796
37. Hasan RN, Schafer AI. Hemin upregulates Egr-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2-Elk-1 and NFkappaB. Circ Res 2008;102:42-50
38. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schönbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem 2002;277:25032-25039
39. Aljada A, Ghanim H, Mohanty P, Syed T, Bandyopadhyay A, Dandona P. Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. Am J Clin Nutr 2004;80:51-57
40. Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011;10:640-647
41. Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGERAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 2010;9:776-784
42. Xu Y, Toure F, Qu W, et al. Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J Biol Chem 2010;285:23233-23240
43. Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA. Aldose reductase inhibition restores endothelial cell function in diabetic rabbit aorta. J Cardiovasc Pharmacol 1993;21:205-211
44. Ramana KV, Bhatnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J 2004;18:1209-1218
45. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28:1137-1143